Carol Nakisige1, Scott V Adams2, Constance Namirembe3, Lazarus Okoche4, James Ferrenberg5, Andrea Towlerton6, Anna Larsen7, Jackson Orem1, Corey Casper8,9,10, Lisa Frenkel10,11,12, Thomas S Uldrick2,13. 1. Uganda Cancer Institute, Kampala, Uganda. 2. Vaccine and Infectious Disease Division and Global Oncology Program, Fred Hutchinson Cancer Research Center, Seattle, WA. 3. Hutchinson Centre Research Institute- Uganda, Kampala, Uganda. 4. Hutchinson Centre Research Institute-Uganda, Fred Hutch, Kampala, Uganda. 5. Fred Hutchinson Cancer Research Center, Seattle, WA. 6. Clinical Research Division and Global Oncology Program, Fred Hutchinson Cancer Research Center, Seattle, WA. 7. Department of Epidemiology, University of Washington, Seattle, WA. 8. Access to Advance Health Institute, Seattle, WA. 9. Departments of Medicine and Global Health, University of Washington, Seattle, WA. 10. Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA. 11. Departments of Pediatrics, Laboratory Medicine and Pathology, Global Health and Medicine, University of Washington, Seattle, WA. 12. Center for Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA; and. 13. University of Washington, Seattle, WA.
Abstract
BACKGROUND: Cervical cancer mortality remains high in sub-Saharan Africa, especially among women living with HIV (WLWH). Characterization of prevalent high-risk human papillomavirus (hrHPV) types and immune function in WLWH with cervical abnormalities despite antiretroviral therapy (ART) can inform prevention strategies. SETTING: Kampala, Uganda. METHODS: From 2017 to 2020, we enrolled Ugandan women with cervical dysplasia detected with visual inspection with acetic acid (VIA). WLWH were required to be on ART >3 months with plasma HIV RNA <1000 copies/mL. Biopsies from VIA-positive lesions underwent histopathologic grading and cervical swab specimens were tested for hrHPV. Clinical correlations were evaluated with Poisson regression to estimate adjusted prevalence ratios (aPR). RESULTS: One hundred eighty-eight WLWH and 116 HIV-seronegative women participated. Among WLWH, median ART duration was 6 years and median CD4 667 cells/µL. Cervical intraepithelial neoplasia (CIN) grade 2/3 was found in 29% of WLWH versus 9% of HIV-seronegative women. In women with CIN1 or without histopathology-confirmed dysplasia, hrHPV (aPR [95% confidence interval]: 2.17 [1.43 to 3.29]) and multiple hrHPV (aPR 3.73 [1.07 to 13.1]) were more common in WLWH, as were vaccine-targeted and vaccine-untargeted hrHPVtypes. Differences in hrHPV prevalence by HIV serostatus were not observed in women with CIN2/3 (interaction P < 0.01). Among WLWH, low CD4/8 ratio was associated with hrHPV while detectable plasma HIV RNA (20-1000 copies/mL) was associated with CIN2/3 or invasive cancer. CONCLUSION: Despite ART, WLWH with cervical VIA abnormalities remain at elevated risk for multiple hrHPV and high-grade dysplasia. Cervical cancer prevention and research tailored for WLWH are warranted in the ART era.
BACKGROUND: Cervical cancer mortality remains high in sub-Saharan Africa, especially among women living with HIV (WLWH). Characterization of prevalent high-risk human papillomavirus (hrHPV) types and immune function in WLWH with cervical abnormalities despite antiretroviral therapy (ART) can inform prevention strategies. SETTING: Kampala, Uganda. METHODS: From 2017 to 2020, we enrolled Ugandan women with cervical dysplasia detected with visual inspection with acetic acid (VIA). WLWH were required to be on ART >3 months with plasma HIV RNA <1000 copies/mL. Biopsies from VIA-positive lesions underwent histopathologic grading and cervical swab specimens were tested for hrHPV. Clinical correlations were evaluated with Poisson regression to estimate adjusted prevalence ratios (aPR). RESULTS: One hundred eighty-eight WLWH and 116 HIV-seronegative women participated. Among WLWH, median ART duration was 6 years and median CD4 667 cells/µL. Cervical intraepithelial neoplasia (CIN) grade 2/3 was found in 29% of WLWH versus 9% of HIV-seronegative women. In women with CIN1 or without histopathology-confirmed dysplasia, hrHPV (aPR [95% confidence interval]: 2.17 [1.43 to 3.29]) and multiple hrHPV (aPR 3.73 [1.07 to 13.1]) were more common in WLWH, as were vaccine-targeted and vaccine-untargeted hrHPVtypes. Differences in hrHPV prevalence by HIV serostatus were not observed in women with CIN2/3 (interaction P < 0.01). Among WLWH, low CD4/8 ratio was associated with hrHPV while detectable plasma HIV RNA (20-1000 copies/mL) was associated with CIN2/3 or invasive cancer. CONCLUSION: Despite ART, WLWH with cervical VIA abnormalities remain at elevated risk for multiple hrHPV and high-grade dysplasia. Cervical cancer prevention and research tailored for WLWH are warranted in the ART era.
Authors: Keith Sigel; Juan Wisnivesky; Kristina Crothers; Kirsha Gordon; Sheldon T Brown; David Rimland; Maria C Rodriguez-Barradas; Cynthia Gibert; Matthew Bidwell Goetz; Roger Bedimo; Lesley S Park; Robert Dubrow Journal: Lancet HIV Date: 2016-12-02 Impact factor: 12.767
Authors: Cecily Banura; Florence M Mirembe; Anne R Katahoire; Proscovia B Namujju; Anthony K Mbonye; Fred M Wabwire Journal: Infect Agent Cancer Date: 2011-07-12 Impact factor: 2.965
Authors: H De Vuyst; N R Mugo; M H Chung; K P McKenzie; E Nyongesa-Malava; V Tenet; J W Njoroge; S R Sakr; Cjl M Meijer; P J F Snijders; F S Rana; S Franceschi Journal: Br J Cancer Date: 2012-10-02 Impact factor: 7.640
Authors: Leigh F Johnson; Joel Mossong; Rob E Dorrington; Michael Schomaker; Christopher J Hoffmann; Olivia Keiser; Matthew P Fox; Robin Wood; Hans Prozesky; Janet Giddy; Daniela Belen Garone; Morna Cornell; Matthias Egger; Andrew Boulle Journal: PLoS Med Date: 2013-04-09 Impact factor: 11.069
Authors: Dominik Stelzle; Luana F Tanaka; Kuan Ken Lee; Ahmadaye Ibrahim Khalil; Iacopo Baussano; Anoop S V Shah; David A McAllister; Sami L Gottlieb; Stefanie J Klug; Andrea S Winkler; Freddie Bray; Rachel Baggaley; Gary M Clifford; Nathalie Broutet; Shona Dalal Journal: Lancet Glob Health Date: 2020-11-16 Impact factor: 26.763